US equities
|
SPCX
$168.37
▲+5.92%
NVDA
$237.35
▲+1.46%
MU
$1,066.57
▼-0.77%
TSLA
$378.75
▲+2.20%
MSFT
$525.51
▲+1.54%
SNDK
$1,715.06
▼-0.29%
INTC
$117.23
▼-1.76%
META
$743.24
▲+2.08%
SPCX
$168.37
▲+5.92%
NVDA
$237.35
▲+1.46%
MU
$1,066.57
▼-0.77%
TSLA
$378.75
▲+2.20%
MSFT
$525.51
▲+1.54%
SNDK
$1,715.06
▼-0.29%
INTC
$117.23
▼-1.76%
META
$743.24
▲+2.08%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Allogene Therapeutics, Inc. - Common Stock
(NQ:
ALLO
)
1.480
-0.020 (-1.33%)
Delayed Quote
Updated: 1:15 PM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Allogene Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases
January 28, 2025
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
December 16, 2024
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman
December 12, 2024
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
A Closer Look at 6 Analyst Recommendations For Allogene Therapeutics
↗
August 08, 2024
Via
Benzinga
Analyst Ratings For Allogene Therapeutics
↗
May 31, 2024
Via
Benzinga
Breaking Down Allogene Therapeutics: 5 Analysts Share Their Views
↗
May 15, 2024
Via
Benzinga
Allogene Therapeutics Announces Participation in December Investor Conferences
November 19, 2024
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence
November 18, 2024
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update
November 07, 2024
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS
November 07, 2024
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for Immunotherapy
November 05, 2024
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Announces Participation in November Investor Conferences
November 04, 2024
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update
October 30, 2024
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ALLO-316, an AlloCAR T™ Investigational Product for Adult Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)
October 29, 2024
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors
October 22, 2024
From
Artiva Biotherapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day Conference
September 30, 2024
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics to Present Pre-Clinical Data Highlighting the Potential of ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Diseases, at the American College of Rheumatology (ACR) Convergence
September 26, 2024
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
August 08, 2024
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
7 Biotech Stocks to Buy for Their Game-Changing Potential
↗
August 08, 2024
Although the market may be reeling from the recent fallout, the red ink presents a viable opportunity in these biotech stocks.
Via
InvestorPlace
Allogene Therapeutics Reports Second Quarter 2024 Financial Results and Business Update
August 07, 2024
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update
July 31, 2024
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Cell Therapy Mostly Used For Blood Cancer Shows Efficacy In Autoimmune Diseases As Well, But There Are Challenges
↗
July 19, 2024
CAR-T therapy, originally used for blood cancers, shows promising results in treating lupus, as evidenced by Janina Paech's remarkable remission. This breakthrough offers new hope for autoimmune...
Via
Benzinga
Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)
July 01, 2024
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse
June 20, 2024
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
If You Can Only Buy One Penny Stock in May, It Better Be One of These 3 Names
↗
May 28, 2024
Penny stocks to buy carry a great deal of risk. However, there are a few that look interesting after due diligence.
Via
InvestorPlace
Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit
May 23, 2024
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Why Larimar Therapeutics Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
↗
May 21, 2024
Via
Benzinga
Why Arcutis Biotherapeutics Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving Premarket
↗
May 15, 2024
Via
Benzinga
Why James Hardie Industries Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
↗
May 21, 2024
Via
Benzinga
DLocal, Allogene Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
↗
May 15, 2024
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
